




## Patient details

Name:

Date of birth:



Family/emergency contact name:

Work Ph:

Mobile Ph:

Plan prepared by:

Doctor:

Signed:

Date:

Contact Ph:

Additional information:

## ACUTE HAE ATTACKS

### Peripheral swelling

- If appropriate administer medication as described below.

### Abdominal pain

- Administer medication as described below.
- Seek urgent hospital treatment if symptoms worsen or last longer than 24 hours.

### ADDITIONAL HOSPITAL TREATMENT:

- Opiate analgesia.
- IV fluid rehydration.
- Give dose of C1-INH (Berinert®) IV if inadequate response after 1 hour.
- Consider other causes of abdominal pain if no response to specific treatment.

### Airway swelling (tongue or throat swelling, difficulty breathing, talking, swallowing).

### Phone ambulance - 000 (AU) or 111 (NZ)

- Seek urgent hospital treatment.
- Administer medication as described below.

### ADDITIONAL HOSPITAL TREATMENT:

- Prepare for emergency intubation or cricothyrotomy.
- Give dose of C1-INH (Berinert®) IV if inadequate response after 1 hour.

## MEDICATION DOSES FOR ACUTE TREATMENT

Medication	Adults and Children >50Kg	Children
Icatibant (Firazyr®) <sup>1,2</sup>	30mg/3ml syringe subcutaneous (SC)	12-25Kg 10mg (1ml) 26-40Kg 15 mg(1.5ml) 41-50Kg 20mg (2ml) subcutaneous (SC)
C1-INH (Berinert®)	20 U/Kg IV	20 U/Kg IV

## SHORT TERM PROPHYLAXIS

For invasive medical, dental procedures, intubation or oropharyngeal instrumentation:

- Administer C1-INH (Berinert®) IV 20 U/Kg, 1-6 hours before procedure
- Have further doses of acute treatment (Firazyr® or Berinert®) available.

## LONG TERM PROPHYLAXIS

Medication and dose:

Not applicable

C1-INH (Berinert®) IV: \_\_\_\_\_

C1-INH (Berinert®) SC: \_\_\_\_\_

Danazol: \_\_\_\_\_

Tranexamic acid: \_\_\_\_\_

### NOTES:

1. Adrenaline, antihistamines and corticosteroids are not effective for HAE attacks.
2. Use patient's own supply either at home or at hospital.
3. Products cited in this plan are TGA and Pharmac registered hence this information is specific for HAE treatment in Australia and New Zealand.
4. Please refer patient for immunology review after hospital presentation.